Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Pregabalin Approved For Marketing In Europe; FDA Review Continues

This article was originally published in The Pink Sheet Daily

Executive Summary

The Neurontin follow-on is approved in the EU for neuropathic pain and as add-on therapy for partial seizures in patients with epilepsy. FDA's user fee deadline for pregabalin (Lyrica) is Oct. 30; Neurontin (gabapentin) generics could hit the market prior to pregabalin's approval.

You may also be interested in...

Neurontin Settlement Of $430 Mil. Is High For Off-Label Case, Low For Pfizer

Pfizer's $430 mil. Neurontin off-label promotion settlement is the equivalent of about nine weeks of U.S. sales of the anti-epileptic brand

Teva, Ivax Move Closer To Marketing Generic Gabapentin; Neurontin Litigation Continues

Ivax receives full ANDA approval for low dose tablet formulations of gabapentin. Teva licenses Alpharma's generic exclusivity for capsule form and higher dose tablets.

US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot

ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts